Urvi Desai
About Urvi Desai
Urvi Desai is the Vice President at Analysis Group in Boston, Massachusetts, with extensive experience in pharmacoeconomics and outcomes research.
Current Role at Analysis Group
Urvi Desai currently holds the position of Vice President at Analysis Group. She has been in this role since 2020, based in Boston, Massachusetts, United States. In her capacity as Vice President, she oversees various analytical and research projects, leveraging her extensive background in pharmacoeconomics and outcomes research.
Previous Positions at Analysis Group
Before becoming Vice President, Urvi Desai served in several capacities at Analysis Group. She was a Manager from 2015 to 2020 in the Greater Boston Area, where she led teams in executing complex economic analysis projects. Prior to that, she worked as an Associate from 2011 to 2015, focusing on pharmacoeconomic studies and policy analysis.
Educational Background
Urvi Desai earned her PhD in Pharmacoeconomics and Outcomes Research from Virginia Commonwealth University (VCU) between 2007 and 2011. Additionally, she holds a B.Pharm from Sardar Patel University, where she studied from 2002 to 2006. Her academic background laid the foundation for her expertise in economic modeling, budget impact analysis, and cost-effectiveness analysis.
Early Career and Internships
Urvi Desai gained diverse experiences during her early career. She interned at Intelliject, Inc and Intelliject LLC, working on projects related to pharmacoeconomics. She also served as a Graduate Teaching Assistant at VCU for three years and held leadership roles in student organizations such as ISPOR's International Student Network and the VCU Student Chapter.
Technical Proficiencies and Expertise
Urvi Desai is proficient in decision modeling using TreeAge software and skilled in conducting Budget Impact Analysis and Cost-Effectiveness Analysis. She is also experienced in using SAS programming for data analysis and Retrospective Database Analysis, particularly with CMS data. Her expertise extends to Public Policy-based Analyses and Patient Reported Outcomes Assessment.